HEADLINES

ARRA Opportunities Continue!
Recently Steven L. Kunkel, Ph.D., Senior Associate Dean for Research, sent an email encouraging faculty to take advantage of ARRA opportunities that have been announced. As in the last few weeks, we expect that more opportunities will be announced and available in the next few weeks. Be sure to watch the UMHS Recovery site for Research for information and updates: (http://www.med.umich.edu/u/recovery/research).

Also, stay in contact with your department grant administrator as eRPM is released and routing procedures are adapted to take advantage of some of the NIH opportunities. They will be your main information source on how to handle things administratively for your unit! (See related article on the eRPM release in the “From the Grants Office” section of this newsletter.)

In order to help facilitate your applications, the Grant Review & Analysis Office is available to answer questions and help you sort through the guidelines. We have had several faculty take advantage of this already. Please contact Heather Offhaus (hmills@umich.edu) or Jane Sierra (jmsierra@umich.edu) at 734-763-4272.

New iFeasible Application for Researchers
If you’re a researcher/investigator, you can now easily check on the feasibility of a study prior to applying for IRB approval. Previously, you would need to ask MCIT to query the Health System Data Warehouse database and then wait for the information. Now you can do it yourself and obtain results almost instantly with this new application developed by MCIT, called “iFeasible.”

Sample size is one of the primary factors that determines the feasibility of a research study, and researchers need to know the number of UMHS patients diagnosed or treated with certain clinical conditions before proceeding. The iFeasible application is a web-based, self-service data query tool that allows users to find out the number of patients from a comprehensive list of diagnoses and procedures used at UMHS, using data from the past ten years. The results are displayed as patient distributions by age group, race, and gender. The application runs on a web browser and does not require the installation of any software. However, in view of the nature of the data, users must register for the service and authenticate whenever they use it. For access to the iFeasible tool, please visit the website (http://www.med.umich.edu/iFeasible/). Email questions to (bir-bis-era@med.umich.edu).

BMRC Bridging Support Program for Basic Science Research
Deadline: May 15, 2009
The Medical School’s Biomedical Research Council (BMRC) is accepting applications for a competitive Bridging Support Program for Basic Science Research. This program provides support to bridge federally funded basic science research grants with a very strong demonstrated likelihood of continued federal funding pending resubmission. Up to $40,000 is available to maintain projects for up to one year. Matching funds from the PI’s department are required. Eligibility is limited to full-time, on-campus instructional and research faculty with primary appointments in the Medical School. Grants to be bridged must reside in the Medical School. Visit (http://www.med.umich.edu/medschool/research/support/funding/bridging.htm) for complete details. For questions, call 734-615-8802 or email (BMRCsubmit@umich.edu).

FDA Commissioner’s Fellowship Program
Deadline: April 15, 2009
The FDA offers a two-year fellowship program, which provides an opportunity for health professionals and other scientists to receive training and experience at the FDA. The objective of the Commissioner’s Fellowship Program is to train a cadre of high accomplished scientists intensively in FDA regulatory science across devices, drugs, biologics, foods, and cosmetics. In addition to classes in each FDA product area, fellows will receive instruction in FDA law, policy and international activities, federal budget process, networking and leadership skills, communication with the public and press, biostatistics, epidemiology, clinical trial design, risk assessment and risk management, and extensive case-based learning classes. In parallel with this didactic training, the fellows, with the guidance of their senior scientist preceptor, will engage in a carefully designed and articulated FDA regulatory science project. This experience can be in a wet lab, with a clinical review or evaluation team, in biostatistics, informatics, epidemiology, risk analysis or another aspect of FDA science.

Applicants must have a Doctoral level degree (M.D., D.O., D.V.M., D.D.S., D.P.M., Pharm.D., or Ph.D.) to be eligible. Applicants with a Bachelor’s degree in an engineering discipline will also be considered. Applicants must be U.S. citizens, non-citizen nationals of the U.S., or have been admitted to the U.S. for permanent residence before the program start date. Applicants cannot be current FDA employees or FDA contractors (such as ORISE fellows). It is expected that when they have completed their fellowship some fellows will remain at FDA. Others may seek jobs in industry or academia where the knowledge and perspective they gained at FDA will prove invaluable. For more information about the program, visit (http://www.fda.gov/commissionersfellowships).
Second Clinical Gene Therapy Trial for Pain Presented
Dr. David Fink, Robert Brear Professor and Chair of the U-M Department of Neurology, presented the protocol for a novel gene therapy for neuropathic pain at the public meeting of the NIH Recombinant DNA Advisory Committee (RAC) on March 3, 2009.

Work by Fink and his collaborators has resulted in the development of a series of gene transfer vehicles (vectors) based on modified Herpes simplex viruses that can be injected into the skin to deliver genes to sensory nerve cells. The first of these vectors, constructed to express the natural opioid peptide enkephalin, is currently in phase 1 clinical trial in patients with pain from cancer at the U-M Cancer Center. The new vector, constructed to cause the release of the inhibitory neurotransmitter gamma amino butyric acid (GABA), is specifically designed to treat pain resulting from nerve damage that occurs in patients with diabetes.

Neuropathic pain is a particularly vexing problem, says Fink. With the best currently available therapies, only one in two patients can expect to achieve a 50 percent reduction in pain. Preclinical studies in animal models demonstrate robust effects from the vector. We are interested to test the therapy now in patients. The trial would be sponsored by Diamyd, a publicly traded Swedish biotechnology company.

Public review by the RAC is the first step in the approval process for novel gene therapies. Fink estimates that the new trial, for patients with pain from diabetic neuropathy, is not likely to be ready for enrollment of the first patients until 2011. The RAC presentation by Dr. Fink on March 3, 2009 can be viewed at (http://videocast.nih.gov/PastEvents.asp?c=39). More information about the research can be found on the Mata-Fink laboratory web site (http://www.med.umich.edu/neurology/mata-fink_lab/).

RESEARCH COMPLIANCE
TRAINING AND EDUCATION

Human Research

OHRP Research Community Forum
Reducing Regulatory Burden:
Real Strategies for Real Change
Thursday, May 14, 2009
7:00 AM - 5:15 PM
Rackham Building / Michigan League

The federal Office for Human Research Protections (OHRP) and the University of Michigan will be co-hosting a Research Community Forum entitled “Reducing Regulatory Burden: Real Strategies for Real Change” on Thursday, May 14, 2009 at U-M Ann Arbor. This national conference will focus on ways to use the flexibility within human research regulations, proposed changes to the regulations, novel approaches to Institutional Review Board (IRB) activities, and demonstrations on decreasing regulatory burdens for researchers and IRBs. Speakers include federal agency and AAHRPP representatives and experts from academia and private IRBs. The conference is open to the public with a registration fee and co-sponsored by UMMS, MICHR, Michigan State University, Northwestern University, Ohio State University, Pennsylvania State University, Purdue University, and the St. Joseph Mercy Health System. Full details are posted at (http://www.research.umich.edu/hrpp/event.html).

Speak To A Regulatory Specialist (STARS) Program
IRBMED is offering a new service as of February 3, 2009 – the Speak To A Regulatory Specialist (STARS) Program. STARS offers set times during the week when a senior regulatory analyst will be available to speak immediately to callers whose inquiry relates to new or ongoing IRBMED business. STARS will be offered on:

- Tuesdays from 10:00 AM - 12:00 PM
- Wednesdays from 1:00 PM - 3:00 PM

This new program supplements, rather than replaces, researchers’ access to IRBMED staff. We still welcome your questions at any time convenient to you, offer consults on new and ongoing research, and educational sessions geared specifically for your needs. If you have any questions, please contact Jan Hewett in the IRBMED office (734-763-4768 or jhewett@umich.edu).

Deception/Incomplete Disclosure Studies
Deception/Incomplete Disclosure Studies: Projects designed to withhold information or provide subjects false information about the research in order to observe the cause of human behavior should undergo careful consideration. The use of deception or incomplete disclosure through an alteration or waiver of documentation is done with the intent to limit information so that subjects do not modify their behavior which could bias data results.

In order to receive a alteration or waiver of informed consent, the Office for Human Research Protections (OHRP) and 45 CFR 46.116 (d) require:
1. The research involves no more than minimal risks to the subjects.
2. The waiver or alteration will not adversely affect the rights and welfare of subjects.
3. The research could not practicably be carried out without the waiver or alteration.
4. Whenever appropriate, the subject will be provided with additional pertinent information after participation.

For research projects involving the use of deception/ incomplete disclosure, investigators and IRBs need to:
1. Assess the validity of the research.
2. Assess whether or not there are alternate methods to conduct the research.
3. Determine whether or not the project could influence the participants’ desire to participate.
4. Describe whether potential harm to the subject through participation can be removed or minimized through debriefing.
5. Address any privacy and confidentiality concerns.

In addition, the IRB examines the research teams’ qualification and experience to conduct this type of research or on a specific population by subject screening. With the IRB and study teams working together throughout the complete process, the approval of these specialized studies should be reachable.
References: (http://www.hhs.gov/ohrp/irb/irb_chapter3.htm) and Institutional Review board: Management and Function. Bankert and Amdur, editors. 2nd ed., 2006, Chapter 6-5. If you have any questions, please contact Jan Hewett in the IRBMED office (734-763-4768 or jhewett@umich.edu).

Animal Research

Animal Use Protocol Reviews
The UCUCA Office has divided up the protocol reviews to provide better support to our principal investigators (PIs). Four compliance associates are handling administrative review of protocols by PI last name.

First Letter of PI’s Last Name  Compliance Associate
A-F  Astrid Haakonstad (astridh@umich.edu)
G-L  Marie Cornell (mhaeussl@umich.edu)
M-R  Sara Waugh (spauly@umich.edu)
S-Z  Matthew Taylor (matttayl@umich.edu)

Feel free to contact your compliance associate directly when working to complete your protocol. Dawn O’Connor, Senior Compliance Associate (oconnord@umich.edu), will continue to oversee all animal facility inspections and the final approval of protocols. In addition, at least once each year, your UCUCA office compliance associates will be visiting with you or your laboratory staff to discuss your approved protocols. During this time, the compliance associate will review your approved protocols with you and provide you with updated information and new policies as it pertains to your laboratory. This is a great opportunity for you to ask any questions you may have about the UCUCA process or policies and regulations.

For additional information about each associate or compliance information, please feel free to visit the UCUCA website (http://www.ucuca.umich.edu). If you have any questions or concerns related to animal care at the University, please do not hesitate to contact us at 734-936-8028 or (ucuca.office@umich.edu).

FREQUENTLY ASKED QUESTIONS
The frequently asked questions (FAQs) highlighted here come from a list of FAQs for research maintained by the Office of Research. To see the complete list, visit (http://www.med.umich.edu/medschool/research/faq.htm).

Q) How do I obtain training and approval to use hazardous agents?
A) OSEH has developed a number of occupational safety and environmental health programs for the continued safety of all UM employees, to encourage safe practices and strong environmental stewardship, and to remain in compliance with State and federal regulations. For more information, visit the OSEH training webpage (http://www.osehtraining.umich.edu/osehtraining/).

FROM THE GRANTS OFFICE

eRPM Is Available!
On March 30, 2009, a campus-wide application for electronic Routing and Proposal Management (eRPM) was released, and MAIS announced the go-live date for eRPM. Selections from the release for tips and training opportunities are included at the bottom of this article.

Faculty will likely find the eRPM system helpful as a central repository of all administrative information around the submission and award of proposals. If you have had a project (as Principal or Participating Investigator identified on the PAF) in the last three years, it will be in the electronic system for viewing. Information available includes: Proposal Approval Form (PAF), Project Award Notices (PAN), and Project Award Changes (PAC). All are attached to the electronic file as viewable PDFs. Then, once the Health System officially “goes live,” the system will be used to route and approve projects to external sponsors. (NOTE: The system does not yet “talk” to eResearch Phase I, IRB – that is on tap for a future enhancement.)

The Health System / Medical School has been listed as “going live” for routing on May 4, 2009. The convergence of both the ARRA initiatives and eRPM release will make the transition challenging. In an attempt to relieve as much stress and confusion from the routing system as possible, the grant administrators across the school held a discussion and collectively decided to use the system to route proposals electronically after May 4, 2009. (This will allow all the NIH Challenge grants, Competitive Revisions, and many of the administrative supplements to be routed on paper without confusing the system with a dual routing path.)

Below is a list of potential activities and appropriate times to use the eRPM system. Hopefully with this built in lead time, the transition from paper to electronics will be as smooth as possible!

• March 30, 2009 – The system went live (http://eresearch.umich.edu).
• March 30, 2009 and after – Use the system to look at previous applications, PAN/PAC notices, and to become acquainted with the system.
• At any point after March 30, 2009 – Begin to build PAFs of projects that will ROUTE May 4, 2009 or after – this includes being able to download Grants.gov forms and prepare them through the system. NOTE: If you want to route a project prior to May 4, 2009, you will need to prepare a paper PAF.
• May 4, 2009 – Route PAFs in the eRPM system.
You are encouraged to use the system and experience it prior to the go-live date in the Health System! In the meantime, if you have any questions, concerns, or implementation questions, please feel free to contact Heather Offhaus (hmills@umich.edu). Watch for further announcements about school-related requirements and materials.

Excerpts from Jim Randolph’s MAIS Announcement of eRPM Release
• System Tips:
  • Enable pop-ups for eResearch – critical to the proper functioning of the eRPM system.
  • To receive email notifications from eResearch, add (eresearch@umich.edu) to your address book/contacts.
  • Plain text email users (e.g., Groupwise) turn on the option to view html messages so that links to system are clickable.
• eRPM Training:
  To support your use of eRPM, we have a variety of training options.
  • Classroom sessions that comprehensively cover PAF creation, the review process, the review routing table, making changes when a PAF is out for review, managing Proposal Data when the proposal is being reviewed, how to review/ approve, and PAN/PAC notifications.
  • The PAF online course which covers the creation of the PAF.
  • Both options, as well as reference material, are available at (http://www.umich.edu/~eresinfo/erpm/training.html).

UPDATE FROM WASHINGTON, DC
NIH Begins to Allocate Economic Stimulus Funds
Following signature into law of the American Recovery and Reinvestment Act (ARRA), the National Institutes of Health (NIH) has begun to allocate the $10.4 billion appropriated to it under the new law. Below is a list of the recent NIH ARRA funding announcements. It is important to note that all information related to ARRA implementation can be found on a new federal website named “recovery.gov” ARRA news specific to NIH can be found at (http://recovery.gov/arranews).

To receive email notifications from eResearch, enable pop-ups for eResearch and add (eresearch@umich.edu) to your address book/contacts. Plain text email users (e.g., Groupwise) turn on the option to view html messages so that links to system are clickable.

EDUCATIONAL OPPORTUNITIES
Annual Biology of Aging Research Retreat
Thursday, May 14, 2009 – 8:30 AM - 4:00 PM
Friday, May 15, 2009 – 8:30 AM - 12:00 PM
Biomedical Science Research Building (BSRB), Room 1150
Sponsored by the University of Michigan Nathan Shock Center for the Biology of Aging
Internationally known biogerontologists will explore recent, and perhaps pending, discoveries likely to provide new directions and unexpected momentum for research in the biology of aging in the coming five to ten years. Speakers include:
• Adam Antebi, Ph.D., Huffington Center on Aging, Baylor School of Medicine
• Andrzej Bartke, Ph.D., Southern Illinois School of Medicine
• Matt Kaeberlein, Ph.D., University of Washington
• Richard Loeser, M.D., Wake Forest University School of Medicine
• Daniel Promislow, Ph.D., University of Georgia
• Nicholas Schork, Ph.D., Scripps Research Institute
• Morris White, Ph.D., Harvard University

To register or for more information, email Jane Heibel at (jheibel@umich.edu).

44th Graduate Summer Session in Epidemiology
Application Deadline: June 1, 2009
(Applications received by the deadline does not guarantee placement in a course. Enrollment is limited in a number of courses.)

The University of Michigan School of Public Health will offer one-week and three-week courses for all public health professionals and those interested in health research during their 44th Graduate Summer Session in Epidemiology to take place July 12-31, 2009. Topics include: Fundamentals of Biostatistics and Epidemiology, Intermediate Methods, Infectious Diseases, Applied Public Health Practice, Cancer Epidemiology, Clinical Trials, SAS, Logistic Model, Linear Regression, Survival Analysis, Behavioral Change, Social Epidemiology, Longitudinal Studies, Global Health, Pharmacoepidemiology, Surveillance, Multi-level Analysis in Public Health, Scientific Writing, Geographic Information Systems, Health Policy, Environmental and Occupational Epidemiology, Community-Based Research, Evolutionary Epidemiology.
• Distance Learning Courses:
  Fundamentals in Biostatistics
  Fundamentals of Epidemiology
• CME credit available

For application and information, visit (http://www.sph.umich.edu/epid/GSS). For questions, contact Jody Gray at 734-764-5454 or (umichgss@umich.edu).

**FUNDING/AWARD OPPORTUNITIES**

Funding opportunities listed below are for external limited submissions and/or opportunities within the University of Michigan only. To search for other funding and recognition opportunities, visit (http://www.med.umich.edu/medschool/research/support/funding.htm). This webpage contains a link to M-Quest (a database of opportunities for grants, honors, prizes and fellowships created and maintained by the Office of Research) as well as information on email alert groups.

*External Limited Submissions*

These are opportunities in which the sponsor has limited the number of proposals allowed from an institution. These competitions require an internal review to select the proposals to submit to the sponsor from the University of Michigan.

Abstracts listed here are general information about these funding programs. We strongly urge interested applicants to visit the listed website to verify complete eligibility, program information, and application procedures before submitting an application.

**William T. Grant Scholars Program**

**Deadline: July 8, 2009**

The William T. Grant Scholars Program supports promising early career researchers from various disciplines. The award is intended to facilitate the professional development of early career scholars who have some demonstrated success in conducting high quality research and are seeking to further develop their skills and research program. Studies from these Scholars contribute to theory and policy/practice for improving the lives of young people.

The Foundation supports research to understand and improve the settings of youth ages 8 to 25 in the United States. Important settings include schools, youth-serving organizations, neighborhoods, families, and peer groups.

Candidates are nominated by a supporting institution*** and must submit five-year research plans that demonstrate creativity, intellectual rigor, and a commitment to continued professional development, are grounded in theory and sound scientific methods, and provide evidence for appropriate mentoring from senior investigators. Every year, four to six William T. Grant Scholars are selected and each receives $350,000 distributed over a five-year period.

The award is designed for early career researchers. Applicants must have received their terminal degree within seven years of submitting their application. The award may not be used as a postdoctoral fellowship. See complete details at (http://www.wtgrantfoundation.org/info-url5243/info-url_show.htm?doc_id=646415).

*** Only one candidate may be nominated per major division of the university. For Medical School faculty, please contact Jyoti Athanikar (jnathani@umich.edu or 734-615-1630) at the Office of Research if you intend to apply so that the necessary internal selection process can be established.

• • • Deadline Watch • • •

**UMMS AWARDED GRANTS**

External Awarded Grants

<table>
<thead>
<tr>
<th>Anesthesiology</th>
</tr>
</thead>
<tbody>
<tr>
<td>PI: Baghdoyan, Helen</td>
</tr>
<tr>
<td>Title: CHOLINERGIC MECHANISMS OF REM SLEEP GENERATION</td>
</tr>
<tr>
<td>Sponsor: NIH 4 R37 MH 045361 22</td>
</tr>
<tr>
<td>Project Dates and Amount of Award: 03/15/09-09/30/11; $1,800,519</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Family Medicine</th>
</tr>
</thead>
<tbody>
<tr>
<td>PI: Green, Lee</td>
</tr>
<tr>
<td>Co-I: Fetters, Michael (Department of Family Medicine) / Nease Jr, Donald (Department of Family Medicine)</td>
</tr>
<tr>
<td>Title: RESEARCH PARTNERSHIP WITH A STATE-WIDE NETWORK OF FEDERALLY QUALIFIED HEALTH CENTERS</td>
</tr>
<tr>
<td>Sponsor: Westat</td>
</tr>
<tr>
<td>Project Dates and Amount of Award: 02/01/09-09/30/09; $100,000</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Graduate and Postdoctoral Studies / Office of Student Programs</th>
</tr>
</thead>
<tbody>
<tr>
<td>PI: Engelke, David</td>
</tr>
<tr>
<td>Co-I: Barald, Kate (MSA PIIBS) / Isom, Lori (MSA PIIBS)</td>
</tr>
<tr>
<td>Title: MICHIGAN POSTBACCALAUREATE RESEARCH EDUCATION PROGRAM</td>
</tr>
<tr>
<td>Sponsor: NIH 1 R25 GM 086262 01</td>
</tr>
<tr>
<td>Project Dates and Amount of Award: 03/01/09-02/28/13; $1,108,148</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Human Genetics</th>
</tr>
</thead>
<tbody>
<tr>
<td>PI: Lenk, Guy</td>
</tr>
<tr>
<td>Title: MECHANISM OF NEURODEGENERATION IN INHERITED PERIPHERAL NEUROPATHY</td>
</tr>
<tr>
<td>Sponsor: Hartwell Foundation</td>
</tr>
<tr>
<td>Project Dates and Amount of Award: 01/01/09-12/31/10; $100,000</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Internal Medicine</th>
</tr>
</thead>
<tbody>
<tr>
<td>PI: Akin, Cem</td>
</tr>
<tr>
<td>Title: RDEA CKIT COMPOUNDS</td>
</tr>
<tr>
<td>Sponsor: Ardea Biosciences</td>
</tr>
<tr>
<td>Project Dates and Amount of Award: 04/01/09-09/30/09; $28,612</td>
</tr>
</tbody>
</table>
Biomedical News • April 2009

Molecular & Behavioral Neuroscience Institute

**Title:** COMPREHENSIVE GENOMIC APPROACH TO RARE HEARING DISORDERS AND ATAIXIA
**Co-I:** Persad, Carol (Psychiatry Department) / Zubieta, Jon (Molecular & Behavioral Neuroscience Institute)
**Project Dates and Amount of Award:** 04/01/09-03/31/10; $22,748

**Title:** BISPHENOL-A AND REPRODUCTIVE DYSFUNCTION
**Co-I:** Artesa, Manuel (Pediatrics-Pulmonary Medicine) / Filbrun, Amy (Pediatrics-Pulmonary Medicine) / Lumeng, Carey (Pediatrics-Pulmonary Medicine) / Tsi, Wan (Pediatrics-Pulmonary Medicine)
**Project Dates and Amount of Award:** 07/09/01-06/30/03; $55,948

Obstetrics & Gynecology

**Title:** TREATMENT FOR OVARIAN CANCER AND THE ROLE OF MGMT IN THE RESPONSE TO THERAPY
**Co-I:** Persad, Carol (Psychiatry Department) / Zubieta, Jon (Molecular & Behavioral Neuroscience Institute)
**Project Dates and Amount of Award:** 01/01/09-08/30/09; $30,764

Neurology

**Title:** USE OF RAC27 REGULATION OF INSULIN SECREPTION
**Co-I:** Segal, Benjamin (Neurology Department) / Srinivasan, Ashok (Radiology Department)
**Project Dates and Amount of Award:** 03/01/09-02/28/13; $1,386,000

Pathology

**Title:** COMPARATIVE GENOMIC STUDY OF TUMORAL AND NORMAL CELLS IN BREAST CANCER
**Co-I:** Segal, Benjamin (Neurology Department) / Srinivasan, Ashok (Radiology Department)
**Project Dates and Amount of Award:** 01/07/09-12/31/09; $54,224

Pediatrics & Communicable Diseases

**Title:** BISEPHENOL-A AND REPRODUCTIVE DYSFUNCTION
**Co-I:** Rappaport, David (Pediatrics-Pulmonary Medicine) / Silverstein, Faye (Pediatrics-Neurology)
**Project Dates and Amount of Award:** 01/01/09-08/30/09; $348,665

Otolaryngology

**Title:** BISPHENOL-A AND REPRODUCTIVE DYSFUNCTION
**Co-I:** Keep, Richard (Otolaryngology Department) / Zubieta, Jon (Molecular & Behavioral Neuroscience Institute)
**Project Dates and Amount of Award:** 04/01/09-03/31/10; $22,748

Physical Medicine & Rehabilitation

**Title:** PERCUITURAL PLASMA DISCECTOMY FOR TREATMENT OF SYMPTOMATIC CERVICAL, THORACIC AND LUMBAR INTERVERTEBRAL DISCS
**Co-I:** Yarjanian, John (Neurology Department) / Tsai, Wan (Pediatrics-Pulmonary Medicine)
**Project Dates and Amount of Award:** 01/01/09-08/30/09; $30,764

**Title:** THE ROLE OF BURKHOLDERIA CENOCEPACIA ADHESIN, ADHA, IN CYSTIC FIBROSIS INFECTIONS
**Co-I:** Segal, Benjamin (Neurology Department) / Srinivasan, Ashok (Radiology Department)
**Project Dates and Amount of Award:** 03/01/09-02/28/10; $10,000

Neurosurgery

**Title:** ENDogenous AND Exogenous PROTECTION OF THE BBB IN STROKE
**Co-I:** Segal, Benjamin (Neurology Department) / Srinivasan, Ashok (Radiology Department)
**Project Dates and Amount of Award:** 01/01/09-08/30/09; $9,600

Obstetrics & Gynecology

**Title:** HORMONES AND COGNITIVE PROCESSING IN EARLY POSTMENOPAUSAL WOMEN
**Co-I:** Persad, Carol (Psychiatry Department) / Zubieta, Jon (Molecular & Behavioral Neuroscience Institute)
**Project Dates and Amount of Award:** 01/01/09-08/30/09; $30,764
Psychiatry

PI: Arnedt, J Todd

Co-I: Armitage, Roseanne (Psychiatry Depression Center) / Hoffmann, Robert (Psychiatry Depression Center) / Langenecker, Scott (Psychiatry-Neuropsychology) / Young, Elizabeth (Molecular & Behav Neurose Inst)

Title: REPEATED PARTIAL SLEEP DEPRIVATION TO AUGMENT SSRI RESPONSE IN DEPRESSION

Sponsor: NIH 1 R01 MH 077690 01 A2

Project Dates and Amount of Award: 03/01/09-12/31/13; $1,738,125

Radiation Oncology

PI: Antonik, Larry

Title: HIGH RESOLUTION MAMMOGRAPHY SENSOR

Sponsor: NIH - Subcontracts TO Radiation Monitoring Devices, Inc.

Project Dates and Amount of Award: 04/01/09-03/31/14; $64,031

Radiology

PI: Kilbourn, Michael

Title: SYNTHESIS AND BIOLOGICAL EVALUATION OF DERIVATIVES OF DIHYDROTETRABENAZINE STEREOISOMERS

Sponsor: Cambridge Laboratories

Project Dates and Amount of Award: 07/01/09-07/31/12; $567,982

Surgery

PI: Adepoju, Linda

Title: TLR8 AS A POTENTIAL THERAPEUTIC TARGET IN SOFT TISSUE SARCOMA

Sponsor: Amer. Medical Association

Project Dates and Amount of Award: 04/01/09-02/28/10; $2,440

PI: Bolling, Steven

Title: JIUCHE BLEND CHEMICAL ANALYSIS

Sponsor: Old Orchard Brands, Llc

Project Dates and Amount of Award: 07/01/09-07/31/12; $1,738,125

PI: Liu, Yang

Co-I: Cooney, Kathleen (Int Med-Hematology/Oncology)

Title: FOXP3 AS X-LINKED TUMOR SUPPRESSOR GENE

Sponsor: NIH DOD-Army, Department of the

Project Dates and Amount of Award: 09/01/09-08/30/10; $64,031

PI: Pagani, Francis

Co-I: Aaronson, Keith (Int Med-Cardiology)

Title: EVALUATION OF THE HEARTWARE LVAD SYSTEM FOR THE TREATMENT OF ADVANCED HEART FAILURE

Sponsor: Heartware, Inc.

Project Dates and Amount of Award: 01/01/12-03/31/13; $567,982

Biological Chemistry


Family Medicine


Mixed methods intervention trials.

Human Genetics


Internal Medicine

Infectious Diseases:


Microbiology and Immunology


Stapleford KA, Rapaport D, Miller DJ, Mitochondrial-Enriched Anionic Functions Determines Granuloma Performance for Controlling Myco-


Obstetrics & Gynecology


Ophthalmology & Visual Sciences


Orthopaedic Surgery


Otolaryngology


Pathology


Cosmos RA, Wright CW, Calbán S, Oetjen KA, Duckett CS. Two distinct signalling cascades trigger the NF-kappaB regulatory factor c-IAP1 for degradation. Biochem J. 2009 Feb 25 (Epub ahead of print).

Biomedical News  •  April 2009


**Pediatrics & Communicable Diseases**


**Radiation Oncology**


**Psychiatry**


**Medicines & Chemicals**
